Ikarian Capital, LLC Tempest Therapeutics, Inc. Transaction History
Ikarian Capital, LLC
- $606 Million
- Q4 2024
A detailed history of Ikarian Capital, LLC transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 105,285 shares of TPST stock, worth $85,280. This represents 0.01% of its overall portfolio holdings.
Number of Shares
105,285
Previous 105,600
0.3%
Holding current value
$85,280
Previous $147,000
40.14%
% of portfolio
0.01%
Previous 0.03%
Shares
5 transactions
Others Institutions Holding TPST
# of Institutions
39Shares Held
6.35MCall Options Held
34.9KPut Options Held
148K-
Versant Venture Management, LLC San Francisco, CA3.51MShares$2.84 Million4.35% of portfolio
-
Black Rock Inc. New York, NY550KShares$445,6950.0% of portfolio
-
Jane Street Group, LLC New York, NY493KShares$399,4060.0% of portfolio
-
Geode Capital Management, LLC Boston, MA354KShares$286,9630.0% of portfolio
-
Ubs Group Ag196KShares$158,4970.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $8.44M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...